LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Latigo Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 3, 2026
$14.30+0.30 (+2.14%)
Close on Oct 19, 2026
- Market cap
- $13.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
SEC filings
3 of Latigo Biotherapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 3, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 3, 2026 | Sep 3, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 10, 2026 | Aug 10, 2026 | SEC EDGAR |